Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
ETON Net Income
Bottom-line profit after all expenses, interest, and taxes.
Eton Pharmaceuticals, Inc.NASDAQ: ETON
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $1.55M, compared with -$1.57M a year earlier. Trailing-twelve-month net income was -$1.48M.
Context
- Net income amounted to 5.8% of revenue in FY2025, down 4.0 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of $58.1M (+1362.8%) for the fiscal year ending Dec 2026, a step up from the -20.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.55M+4.8% QoQ
- Last fiscal yearDec 2025
- -$4.6M-20.4% YoY
- LTMMar 2026
- -$1.48M+67.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +198.9% | +344.2% | +145.4 pp |
| 1 year | -20.4% | +1362.8% | +1383.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (4.6M) USD
- Year-over-year change
- -20.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4.6M) | -20.4% |
| FY2024 | 2024-12-31 | (3.82M) | -308.4% |
| FY2023 | 2023-12-31 | (936K) | +89.6% |
| FY2022 | 2022-12-31 | (9.02M) | -361.4% |
| FY2021 | 2021-12-31 | (1.96M) | — |
Net Income vs competitors
How ETON compares with its peers on the latest reported figures
- ETON's LTM Mar 2026 net income of -$1.48M is the 3rd highest of the 10 companies compared; the peer median is -$35.1M.
- Its year-over-year change of +67.8% is the 4th highest of 10, against a peer median of -10.9%.
- Net income amounts to 1.7% of revenue for ETON, versus a peer median of 37.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.22M | +235.0% | — | 101.6% | |
| LTM Mar 2026 | $12.33M | +187.5% | -40.6% | 3.3% | |
| LTM Mar 2026 | -$1.48M | +67.8% | — | 1.7% | |
| LTM Mar 2026 | -$8.38M | +42.0% | — | 16.4% | |
| LTM Mar 2026 | -$26.09M | +85.3% | — | 37.5% | |
| LTM Mar 2026 | -$35.1M | -30.0% | — | — | |
| LTM Sep 2026 | -$121.51M | -37.2% | — | 18.7% | |
| LTM Mar 2026 | -$166.01M | -74.3% | — | — | |
| LTM Sep 2026 | -$546.15M | -113.1% | — | 56.9% | |
| LTM Mar 2026 | -$609.36M | -10.9% | — | 91.0% | |
| Peer median (excluding ETON) | -$35.1M | -10.9% | -40.6% | 37.5% | |
Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 21.83M | 21.25M | 31.64M | 39.01M | 79.95M |
| Cost of Revenue | 2.62M | 6.93M | 10.58M | 15.6M | 37.21M |
| Gross Profit | 19.21M | 14.32M | 21.06M | 23.41M | 42.74M |
| Gross Margin | 88.0% | 67.4% | 66.6% | 60.0% | 53.5% |
| Research & Development | 6.24M | 4M | 3.32M | 3.26M | 7.77M |
| Selling, General & Admin | 14.47M | 18.58M | 18.93M | 22.75M | 35.82M |
| Operating Expenses | 20.7M | 22.58M | 22.25M | 26.01M | 42.67M |
| Depreciation & Amortization | 462K | 1.77M | 901K | 1.15M | 4.04M |
| EBITDA | (1.49M) | (7.25M) | 212K | (657K) | 4.27M |
| EBITDA Margin | -6.8% | -34.1% | 0.7% | -1.7% | 5.3% |
| Operating Income | (1.5M) | (8.26M) | (1.19M) | (2.6M) | 72K |
| Operating Margin | -6.8% | -38.9% | -3.8% | -6.7% | 0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.04M | 955K | 1.06M | 2.01M | 4.78M |
| Other Income / Expenses | (460K) | (761K) | 503K | (1.21M) | (4.63M) |
| Income Before Tax | (1.96M) | (9.02M) | (689K) | (3.81M) | (4.56M) |
| Pre-Tax Margin | -9.0% | -42.4% | -2.2% | -9.8% | -5.7% |
| Income Tax Expense | 0 | 0 | 247K | 15K | 43K |
| Net Income | (1.96M) | (9.02M) | (936K) | (3.82M) | (4.6M) |
| Net Margin | -9.0% | -42.4% | -3.0% | -9.8% | -5.8% |
| EPS (Basic) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| EPS (Diluted) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| Weighted Avg Shares | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
| Weighted Avg Shares (Diluted) | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.